• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Clarus Therapeutics Holdings Inc. (Amendment)

    2/4/22 11:49:49 AM ET
    $CRXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRXT alert in real time by email
    SC 13G/A 1 bluwu13ga31dec2021.htm Converted by EDGARwiz

    CUSIP NO. 18271L107

    SCHEDULE 13G/A

    PAGE 1 OF 10 PAGES


                               

    ===============================================================================

                               

                                      UNITED STATES                                 

                           SECURITIES AND EXCHANGE COMMISSION                       

                                 WASHINGTON, D.C. 20549                             

                               

                                      SCHEDULE 13G/A                                 

                               

                        Under the Securities Exchange Act of 1934                   

                                    (Amendment No. 2)*                             

                             

                               

    CLARUS THERAPEUTICS HOLDINGS, INC. (FORMERLY KNOWN AS BLUE WATER ACQUISITION CORP.)

    -------------------------------------------------------------------------------

                                    (Name of Issuer)                                

                               

                               

    Common stock, par value $0.0001 per share

    -------------------------------------------------------------------------------

                             (Title of Class of Securities)                         

                               


                                       18271L107

    -------------------------------------------------------------------------------

                                     (CUSIP Number)                                 

                               


    December 31, 2021

    -------------------------------------------------------------------------------

                 (Date of Event Which Requires Filing of This Statement)            

                               

    Check the appropriate box to designate the rule pursuant to which this Schedule

    is filed:                  

                                 [ ] Rule 13d-1(b)                                  

                                 [X] Rule 13d-1(c)                                  

                                 [ ] Rule 13d-1(d)                                  

                                           

    * The remainder of this cover page shall be filled out for a reporting person's

    initial filing on this form with respect to the subject class of securities, and

    for any subsequent   amendment   containing   information  which  would  alter

    disclosures provided in a prior cover page.                                     

                               

    The information required on the remainder of this cover page shall not be deemed

    to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of

    1934 ("Act") or otherwise subject to the liabilities of that section of the Act

    but shall be  subject  to all other  provisions  of the Act  (however, see the

    Notes).



    CUSIP NO. 18271L107

    SCHEDULE 13G/A

    PAGE 2 OF 10 PAGES


    --------------------------------------------------------------------------------

    1.               NAME OF REPORTING PERSON/S.S. OR I.R.S. IDENTIFICATION       

                      NO. OF ABOVE PERSON                                          

                               

                      WEISS ASSET MANAGEMENT LP                                  

    --------------------------------------------------------------------------------

    2.                CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   

                     (A) [ ]  

                     (B) [ ]   

    --------------------------------------------------------------------------------

    3.                SEC USE ONLY                                                 

                               

                               

    --------------------------------------------------------------------------------

    4.                CITIZENSHIP OR PLACE OF ORGANIZATION                         

                               

                      DELAWARE

    --------------------------------------------------------------------------------

                                   5.     SOLE VOTING POWER                        

                               

                                          0                                        

       NUMBER OF                  --------------------------------------------------

        SHARES                     6.     SHARED VOTING POWER                      

     BENEFICIALLY              

    OWNED BY                          0               

     EACH                      --------------------------------------------------

      REPORTING                    7.     SOLE DISPOSITIVE POWER                  

       PERSON                  

        WITH:                             0                                       

                                  --------------------------------------------------

                                   8.     SHARED DISPOSITIVE POWER                

                               

                                          0

    --------------------------------------------------------------------------------

    9.                AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                               

                      0

    --------------------------------------------------------------------------------

    10.               CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES        

                      CERTAIN SHARES*                                          [ ]

    --------------------------------------------------------------------------------

    11.               PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)           

                               

                      0.00%     

    --------------------------------------------------------------------------------

    12.               TYPE OF REPORTING PERSON*                                  

                               

                      IA – Investment Adviser                             




    CUSIP NO. 18271L107

    SCHEDULE 13G/A

    PAGE 3 OF 10 PAGES


    --------------------------------------------------------------------------------

    1.               NAME OF REPORTING PERSON/S.S. OR I.R.S. IDENTIFICATION       

                      NO. OF ABOVE PERSON                                          

                               

                      BIP GP LLC                                  

    --------------------------------------------------------------------------------

    2.                CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   

                     (A) [ ]  

                     (B) [ ]   

    --------------------------------------------------------------------------------

    3.                SEC USE ONLY                                                 

                               

                               

    --------------------------------------------------------------------------------

    4.                CITIZENSHIP OR PLACE OF ORGANIZATION                         

                               

                      DELAWARE

    --------------------------------------------------------------------------------

                                   5.     SOLE VOTING POWER                        

                               

                                          0                                        

       NUMBER OF                  --------------------------------------------------

        SHARES                     6.     SHARED VOTING POWER                      

     BENEFICIALLY              

    OWNED BY                          0               

     EACH                      --------------------------------------------------

      REPORTING                    7.     SOLE DISPOSITIVE POWER                  

       PERSON                  

        WITH:                             0                                       

                                  --------------------------------------------------

                                   8.     SHARED DISPOSITIVE POWER                

                               

                                          0

    --------------------------------------------------------------------------------

    9.                AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                               

                      0

    --------------------------------------------------------------------------------

    10.               CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES        

                      CERTAIN SHARES*                                          [ ]

    --------------------------------------------------------------------------------

    11.               PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)           

                               

                      0.00%     

    --------------------------------------------------------------------------------

    12.               TYPE OF REPORTING PERSON*                                  

                               

                      00 – Limited Liability Company                             



    CUSIP NO. 18271L107

    SCHEDULE 13G/A

    PAGE 4 OF 10 PAGES


    --------------------------------------------------------------------------------

    1.               NAME OF REPORTING PERSON/S.S. OR I.R.S. IDENTIFICATION       

                      NO. OF ABOVE PERSON                                          

                               

                      WAM GP LLC                                  

    --------------------------------------------------------------------------------

    2.                CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   

                     (A) [ ]  

                     (B) [ ]   

    --------------------------------------------------------------------------------

    3.                SEC USE ONLY                                                 

                               

                               

    --------------------------------------------------------------------------------

    4.                CITIZENSHIP OR PLACE OF ORGANIZATION                         

                               

                      DELAWARE

    --------------------------------------------------------------------------------

                                   5.     SOLE VOTING POWER                        

                               

                                          0                                        

       NUMBER OF                  --------------------------------------------------

        SHARES                     6.     SHARED VOTING POWER                      

     BENEFICIALLY              

    OWNED BY                          0               

     EACH                      --------------------------------------------------

      REPORTING                    7.     SOLE DISPOSITIVE POWER                  

       PERSON                  

        WITH:                             0                                       

                                  --------------------------------------------------

                                   8.     SHARED DISPOSITIVE POWER                

                               

                                          0

    --------------------------------------------------------------------------------

    9.                AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                               

                      0

    --------------------------------------------------------------------------------

    10.               CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES        

                      CERTAIN SHARES*                                          [ ]

    --------------------------------------------------------------------------------

    11.               PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)           

                               

                      0.00%     

    --------------------------------------------------------------------------------

    12.               TYPE OF REPORTING PERSON*                                  

                               

                      HC – Parent Holding Company/Control Person                            





    CUSIP NO. 18271L107

    SCHEDULE 13G/A

    PAGE 5 OF 10 PAGES


    --------------------------------------------------------------------------------

    1.               NAME OF REPORTING PERSON/S.S. OR I.R.S. IDENTIFICATION      

                      NO. OF ABOVE PERSON                                         

                               

                      ANDREW M. WEISS, PH.D.                                      

    --------------------------------------------------------------------------------

    2.                CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   

                      (A) [ ]

                      (B) [ ]   

    --------------------------------------------------------------------------------

    3.                SEC USE ONLY                                                

                               

                               

    --------------------------------------------------------------------------------

    4.                CITIZENSHIP OR PLACE OF ORGANIZATION                        

                               

                      USA      

    --------------------------------------------------------------------------------

                                   5.     SOLE VOTING POWER                       

                               

                                          0                                       

       NUMBER OF                  --------------------------------------------------

        SHARES                     6.     SHARED VOTING POWER                      

     BENEFICIALLY              

    OWNED BY                          0               

     EACH                      --------------------------------------------------

      REPORTING                    7.     SOLE DISPOSITIVE POWER                  

       PERSON                  

        WITH:                             0                                       

                                  --------------------------------------------------

                                   8.     SHARED DISPOSITIVE POWER               

                               

                                          0

    --------------------------------------------------------------------------------

    9.                AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                               

                      0

    --------------------------------------------------------------------------------

    10.               CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES       

                      CERTAIN SHARES*                                          [ ]

    --------------------------------------------------------------------------------

    11.               PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)           

                               

                      0.00%    

    --------------------------------------------------------------------------------

    12.               TYPE OF REPORTING PERSON*                                  

                               

                      HC – Parent Holding Company/Control Person       




    CUSIP NO. 18271L107

    SCHEDULE 13G/A

    PAGE 6 OF 10 PAGES


    ITEM 1.                    

                               

          (a) Name of Issuer:  CLARUS THERAPEUTICS HOLDINGS, INC. (FORMERLY KNOWN AS BLUE WATER ACQUISITION CORP.)

                             ------------------------------------------------

                              

          (b) Address of Issuer's Principal Executive Offices:    

    555 Skokie Boulevard

    Suite 340

    Northbrook, IL 60062

                    ------------------------------------------------                   ITEM 2.                    

                               

          (a) and (c): Name and Citizenship of Persons Filing:                    

                               

     (i)   BIP GP LLC, a Delaware limited liability company (“BIP GP”).

     (ii)  Weiss Asset Management LP, a Delaware limited partnership ("Weiss        Asset Management").

    (iii)   WAM GP LLC, a Delaware limited liability company (“WAM GP”).

           (iv)  Andrew M. Weiss, Ph.D., a United States citizen (“Andrew Weiss”).      

                               

          (b):  Address of Principal Business Office:                            

                               

          BIP GP, Weiss Asset Management, WAM GP, and Andrew Weiss have a business    

          address of 222 Berkeley St., 16th floor, Boston, Massachusetts 02116

                               

          (d) Title of Class of Securities: Common stock, par value $0.0001 per share

             

    -------------------------------------                        

          (e) CUSIP Number: 18271L107

                           ------------------                      

                 

    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B), CHECK

            WHETHER THE PERSON FILING IS A:                                         

                               

         (a)  [ ] Broker or Dealer registered under Section 15 of the Act           

                  (15 U.S.C. 78o).                                                  

         (b)  [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).    

         (c)  [ ] Insurance Company as defined in section 3(a)(19) of the Act       

                  (15 U.S.C. 78c).                                                  

         (d)  [ ] Investment  Company  registered  under section 8 of the Investment

                  Company Act of 1940 (15 U.S.C. 80a-8).                            

         (e)  [ ] Investment  Adviser registered under section 203 of the Investment

                  Advisers Act or under the laws of any State                       

         (f)  [ ] Employee  Benefit  Plan,  Pension  fund  which is  subject to the

                  provisions of the Employee  Retirement  Income Security Act of    

                  1974 or Endowment Fund; see Section 240.13d-1(b)(1)(ii)(F)        

         (g)  [ ] A Parent Holding Company  or  control  person, in  accordance with

                  Section 240.13d-1(b)(ii)(G)                     

         (h)  [ ] A Savings  Association  as defined in Section  3(b) of the Federal

                  Deposit Insurance Act (12 U.S.C. 1813)                            

         (i)  [ ] A  Church  Plan  that  is  excluded  from  the  definition  of  an

                  investment  company under Section  3(c)(14) of the Investment     

                  Company Act of 1940 (15 U.S.C. 80a-3)                             

         (j)  [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J)          

                               



    CUSIP NO. 18271L107

    SCHEDULE 13G/A

    PAGE 7 OF 10 PAGES


    ITEM 4.   OWNERSHIP        

                               

    BIP GP*                                             

          (a) Amount Beneficially Owned:  0

                                         -------------------------------------------

          (b) Percent of Class:  0.00%                                               

                                ----------------------------------------------------

          (c) Number of shares as to which such person has:                         

                               

            (i)   sole power to vote or to direct the vote:   0                    

                                                             -----------------------

            (ii)  shared power to vote or to direct the vote:  0

                                                               ---------------------

            (iii) sole power to dispose or to direct the disposition of:  0         

                                                                          ----------

            (iv)  shared power to dispose or to direct the disposition of: 0

                                                                           ----------                  


    WEISS ASSET MANAGEMENT*                                             

          (a) Amount Beneficially Owned:  0

                                         -------------------------------------------

          (b) Percent of Class:  0.00%                                               

                                ----------------------------------------------------

          (c) Number of shares as to which such person has:                         

                               

            (i)   sole power to vote or to direct the vote:   0                    

                                                             -----------------------

            (ii)  shared power to vote or to direct the vote:  0

                                                               ---------------------

            (iii) sole power to dispose or to direct the disposition of:  0         

                                                                          ----------

            (iv)  shared power to dispose or to direct the disposition of: 0

                                                                           ----------                  


    WAM GP*                                             

          (a) Amount Beneficially Owned:  0

                                         -------------------------------------------

          (b) Percent of Class:  0.00%                                            

                                ----------------------------------------------------

          (c) Number of shares as to which such person has:                         

                               

            (i)   sole power to vote or to direct the vote:    0                    

                                                             -----------------------

            (ii)  shared power to vote or to direct the vote:  0

                                                               ---------------------

            (iii) sole power to dispose or to direct the disposition of:  0         

                                                                          ----------

            (iv)  shared power to dispose or to direct the disposition of: 0

                                                                           ----------                     


      ANDREW M. WEISS, PH.D.*                         

          (a) Amount Beneficially Owned:  0

                                         -------------------------------------------

          (b) Percent of Class:  0.00%                                           

                                ----------------------------------------------------

          (c) Number of shares as to which such person has:                         



    CUSIP NO. 18271L107

    SCHEDULE 13G/A

    PAGE 8 OF 10 PAGES


                               

            (i)  sole power to vote or to direct the vote:    0                    

                                                            ------------------------

            (ii) shared power to vote or to direct the vote:  0

        

        -----------------------

            (iii) sole power to dispose or to direct the disposition of:   0         

                    

       -----------

            (iv) shared power to dispose or to direct the disposition of: 0

                                                                          -----------


    -----------------------    

    * Shares reported for BIP GP include shares beneficially owned by a private investment partnership (the “Partnership”) of which BIP GP is the sole general partner. Weiss Asset Management is the sole investment manager to the Partnership. WAM GP is the sole general partner of Weiss Asset Management. Andrew Weiss is the managing member of WAM GP and BIP GP. Shares reported for WAM GP, Andrew Weiss and Weiss Asset Management include shares beneficially owned by the Partnership (and reported above for BIP GP).


    Each of BIP GP, WAM GP, Weiss Asset Management, and Andrew Weiss disclaims beneficial ownership of the shares reported herein as beneficially owned by each except to the extent of their respective pecuniary interest therein. The percent of class computations are based on 24,750,011 shares of Common stock, par value $0.0001 per share, issued and outstanding as of December 3, 2021 as calculated from the Form 8-K of the Issuer, which was filed with the SEC on December 7, 2021.



    ITEM 5.   OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS                         

                               

             If this statement is being filed to report the fact that as of the date

    hereof the reporting person has ceased to be the beneficial  owner of more than

    five percent of the class of securities, check the following [X].

                               

                               

    ITEM 6.   OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON       

                               

          Not Applicable       

                               

                               

    ITEM 7.  IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE

             SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL

             PERSON            

                               

          See Item 4.       

                               

                               

    ITEM 8.   IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP             

                               

          Not Applicable       



    ITEM 9.   NOTICE OF DISSOLUTION OF GROUP                                        

                               

          Not Applicable                                  



    CUSIP NO. 18271L107

    SCHEDULE 13G/A

    PAGE 9 OF 10 PAGES


    ITEM 10.  CERTIFICATION    

                               

    By signing below I certify that, to the best of my knowledge and belief, the

    securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.    



    ITEM 11.  MATERIALS TO BE FILED AS EXHIBITS


    Exhibit 1

    Joint Filing Agreement    


      SIGNATURE                                   

                               

    After reasonable inquiry and to the best of my knowledge and belief, I hereby

    certify that the information set forth in this statement is true, complete and

    correct.                   

                               

    Dated:  February 4, 2022     

                               WEISS ASSET MANAGEMENT LP            


    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Chief Compliance Officer



    BIP GP LLC            


    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Chief Compliance Officer



    WAM GP LLC

        

    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Chief Compliance Officer



    ANDREW M. WEISS, PH.D.                         

        

    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Attorney-in-Fact for Andrew Weiss**


    _____

    ** Duly authorized under Power of Attorney incorporated herein by reference to the exhibit to the Form 13G/A filed by Weiss Asset Management LP on January 25, 2017 in respect of its holding in Quinpario Acquisition Corp. 2.



    CUSIP NO. 18271L107

    SCHEDULE 13G/A

    PAGE 10 OF 10 PAGES


    Exhibit 1

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, Weiss Asset Management LP, BIP GP LLC, WAM GP LLC, and Andrew M. Weiss, hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G and/or 13D (including any and all amendments thereto) with respect to the Class A common stock, par value $0.0001 per share of BLUE WATER ACQUISITION CORPORATION, and further agree that this Joint Filing Agreement, as may be amended from time to time, shall be included as an Exhibit to such joint filings.

     

    The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and/or 13D and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

     

    This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.

     

    IN WITNESS WHEREOF, the undersigned have executed this Agreement as of December 23, 2020 .


                               WEISS ASSET MANAGEMENT LP            


    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Chief Compliance Officer



    BIP GP LLC            


    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Chief Compliance Officer


                                                                                                             

    WAM GP LLC

        

    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Chief Compliance Officer



    ANDREW M. WEISS, PH.D.                         

        

    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Attorney-in-Fact for Andrew Weiss**


    ** Duly authorized under Power of Attorney incorporated herein by reference to the exhibit to the Form 13G/A filed by Weiss Asset Management LP on January 25, 2017 in respect of its holding in Quinpario Acquisition Corp. 2.



    Get the next $CRXT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CRXT

    DatePrice TargetRatingAnalyst
    10/13/2021$10.00Buy
    Truist Securities
    10/6/2021$12.00Buy
    Needham
    9/29/2021$13.00Buy
    Maxim Group
    More analyst ratings

    $CRXT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder

      Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC:CRXTQ), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that, subject to entry into definitive documentation, it and its wholly-owned subsidiary, Clarus Therapeutics, Inc., selected Tolmar, Inc., (Buffalo Grove, IL) as the winning bidder in a competitive bidding and auction proceeding for the sale of JATENZO (and certain related assets). The bidding and auction procedures were approved by the U. S. Ba

      10/18/22 4:05:00 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

      NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court). Clarus has also filed a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code of its sole commercial asset, JATENZO, that is approved for use by healthcare providers to treat testos

      9/5/22 10:19:04 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction

      Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year Immediate reduction in workforce by approximately 40% of total headcount; transition of Chief Financial Officer role NORTHBROOK, Ill., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies, today reported financial results for the second quarter of 2022. Clarus also announced that it is pursuing an immediate reduction in staff as i

      8/18/22 4:05:07 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Prygocki Mark A Sr was granted 1,922 shares, increasing direct ownership by 50% to 5,766 units

      4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      6/9/22 8:06:00 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Murphy Kimberly M was granted 1,922 shares, increasing direct ownership by 50% to 5,766 units

      4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      6/9/22 8:04:31 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Amory John Kenneth was granted 1,922 shares, increasing direct ownership by 50% to 5,766 units

      4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      6/9/22 8:02:52 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Clarus Therapeutics Holdings Inc.

      15-12G - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      3/1/23 7:35:06 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Holdings Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Other Events

      8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      3/1/23 7:26:43 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Clarus Therapeutics Holdings Inc.

      S-8 POS - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      3/1/23 7:22:23 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist Securities initiated coverage on Clarus Therapeutics Hldgs with a new price target

      Truist Securities initiated coverage of Clarus Therapeutics Hldgs with a rating of Buy and set a new price target of $10.00

      10/13/21 7:15:13 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Clarus Therapeutics Hldgs with a new price target

      Needham initiated coverage of Clarus Therapeutics Hldgs with a rating of Buy and set a new price target of $12.00

      10/6/21 6:00:16 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Clarus Therapeutics with a new price target

      Maxim Group initiated coverage of Clarus Therapeutics with a rating of Buy and set a new price target of $13.00

      9/29/21 8:32:42 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    Leadership Updates

    Live Leadership Updates

    See more
    • Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer

      Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck's HPV/Gardasil Franchise. Ms. Murphy joined Oragenics' Board of Directors in 2020. "As a Board Member, Ms. Murphy's extensive experience in the vaccine industry has provided valuable insight for Oragenics' corporat

      6/23/22 4:30:00 PM ET
      $BWV
      $CRXT
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer

      Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the appointment of Zhanna Jumadilova, M.D., M.B.A., as Chief Clinical Development Officer, effective January 17, 2022. Dr. Jumadilova has nearly 30 years of experience in the pharmaceutical and biotech industries. She most recently led clinical development programs

      1/18/22 9:05:00 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    Financials

    Live finance-specific insights

    See more
    • Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

      NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its first quarter 2022 financial and operating results on Monday, May 16, 2022, after the market closes. Clarus will host a conference call on Monday, May 16, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 7677008. A live webcast and replay of the conference call will be

      5/12/22 9:05:00 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

      2021 net revenue increased 119% year-over-year to $14.0 million Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 million Fourth quarter 2021 total prescription growth for JATENZO® increased 11% sequentially and increased 81% year-over-year Conference call and webcast today at 5:15 p.m. ET NORTHBROOK, Ill., March 30, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today reported financial results for the fourth quarter and full year of 2021. "Clarus delivered solid growth in net revenu

      3/30/22 4:05:00 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results

      NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its fourth quarter and full year 2021 financial and operating results on Wednesday, March 30, 2022, after the market closes. Clarus will host a conference call on Wednesday, March 30, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 5454819. A live webcast and replay of the

      3/29/22 4:05:00 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Clarus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      2/14/23 12:29:21 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Clarus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      7/6/22 4:00:10 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Clarus Therapeutics Holdings Inc. (Amendment)

      SC 13D/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      4/21/22 8:43:02 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care